RxDoctor Payments Data

Jithin Yohannan

Ophthalmology · Baltimore, MDNPI 1699047787

Payments from drug & device makers

$17,915in general payments, 2019–2025

Across 30 payments — averaging $597.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$14K
  • Topcon Healthcare, Inc.$4K
  • Ivantis, Inc$583
  • Sight Sciences, Inc.$46
  • Alcon$24
  • Johnson & Johnson Surgical Vision, Inc.$22
  • plus $13 from 1 others

What the payments were for

  • Consulting fees$14,23879%
  • Speaking & faculty fees$1,5008%
  • Travel & lodging$1,3758%
  • Food & beverage$8024%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,915 in reported general payments places this provider in the 85th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$636,346
Medicare patients
870
Services billed
4,584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate47$24,761
LumiganBimatoprost39$22,019
Travoprost39$8,929
Latanoprost474$8,602
Brimonidine Tartrate117$5,041
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat197$3,735
TafluprostTafluprost/Pf16$3,702
SimbrinzaBrinzolamide/Brimonidine Tart14$3,595
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$3,479
Prednisolone Acetate73$3,203
Dorzolamide-TimololDorzolamide/Timolol/Pf20$2,699
Timolol Maleate149$1,509
Ketorolac Tromethamine82$1,394
Dorzolamide Hcl59$1,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$13,726$22,01939 claims
AlconSimbrinza$24$3,59514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →